In January 2024 a New Jersey Pilates teacher, Debi Weiss, dismissed growing breathlessness and fatigue as the flu until symptoms escalated and she sought medical care in March. Tests revealed diffuse large B-cell lymphoma, an aggressive blood cancer that had returned and spread to her brain after initial chemotherapy. Her care team at Atlantic Health Morristown Medical Center recommended personalized CAR‑T cell therapy, which Weiss received in January 2025. As of March 2026 she is in complete remission and continues routine scans to monitor for recurrence.
Key Takeaways
- Patient timeline: symptoms began January 2024, initial diagnosis in March 2024, CAR‑T infusion in January 2025, monitored for one year and now in complete remission (March 2026).
- Diagnosis: diffuse large B‑cell lymphoma, a common and fast‑growing subgroup of lymphomas with roughly 25,000 U.S. cases per year.
- Treatment choice: CAR‑T immunotherapy was selected after lymphoma recurred in the brain one month post‑chemotherapy; CAR‑T cells are engineered T‑cells infused back into the patient.
- Procedure details: the engineered cell infusion typically takes 20–30 minutes and patients are commonly observed in hospital for one to two weeks because of potential neurotoxicity.
- Outcome: Weiss experienced no reported acute side effects from CAR‑T, regained daily function, and is currently without evidence of disease while undergoing periodic scans every four to six months.
- Prognosis note: clinicians said if remission holds for three years the chance of recurrence is substantially lower.
Background
Diffuse large B‑cell lymphoma (DLBCL) is the most frequent type of non‑Hodgkin lymphoma, representing a fast‑growing malignancy of B lymphocytes. In the United States clinicians diagnose roughly 25,000 new cases of DLBCL annually; it can present with systemic symptoms such as fatigue and shortness of breath that may be mistaken for common illnesses like influenza. First‑line treatment commonly includes combination chemotherapy, which attacks rapidly dividing cells but can fail if cancer recurs quickly afterward. When relapse occurs soon after standard chemotherapy, oncologists often consider biologic options that harness the immune system rather than additional cytotoxic regimens.
CAR‑T (chimeric antigen receptor T‑cell) therapy has emerged over the past decade as one such biologic option, approved for several blood cancers including relapsed or refractory DLBCL. The approach removes a patient’s T cells, engineers them to target tumor antigens, expands them in the lab, and reinfuses them into the bloodstream. Given the therapy’s power and risks — notably cytokine release syndrome and neurologic toxicity — patients typically undergo inpatient monitoring for days to weeks post‑infusion. Use is concentrated at specialized centers and is expanding in clinical trials for other hematologic and autoimmune conditions.
Main Event
Debi Weiss first noticed progressive weakness and trouble breathing in January 2024 but delayed care until March when symptoms became debilitating and she could no longer walk her dog. Primary care evaluation triggered blood work and imaging; a biopsy confirmed diffuse large B‑cell lymphoma. Weiss began standard chemotherapy and initially tolerated treatment with fatigue as the main side effect, according to her treatment team.
One month after completing chemotherapy, Weiss developed neurologic symptoms that prompted repeat imaging; clinicians found the lymphoma had recurred and involved the brain. Her hematologist‑oncologist, Dr. Charles Farber at Atlantic Health Morristown Medical Center, described her outlook as poor without a different approach. The multidisciplinary team evaluated Weiss for personalized CAR‑T therapy, explaining potential benefits and risks and obtaining approval and preparation for the procedure.
In January 2025 Weiss received the engineered T‑cell infusion. The transfer of cells into her bloodstream took roughly 20–30 minutes; nursing staff monitored cognitive and neurologic status closely afterward. Weiss later described a vivid impression of her reinfused cells attacking the tumor, an image staff lightened with whiteboard drawings during her stay. Over the following days and weeks she showed no acute complications such as neurotoxicity or cytokine release syndrome and was discharged to continue outpatient follow‑up.
Following the infusion Weiss returned to normal activities: walking her dog, resuming part‑time work and participating in survivor support activities. Atlantic Health clinicians report she remained under surveillance with scans every four to six months. As of the latest clinical update she has no evidence of disease; the team will continue periodic imaging and follow‑up care to detect any recurrence early.
Analysis & Implications
Weiss’s case illustrates how DLBCL can masquerade as benign viral illness initially and underscores the importance of clinical vigilance when systemic symptoms persist. Early recognition and biopsy are crucial because DLBCL often progresses rapidly; delayed diagnosis can narrow therapeutic options. Clinicians balance the toxicity of repeat chemotherapy with the potential durability of immune‑based therapies when disease recurs shortly after standard treatment.
CAR‑T therapy represents a paradigm shift for relapsed hematologic malignancies: by genetically programming a patient’s immune cells to target cancer, it can produce deep, durable remissions that traditional cytotoxic chemotherapy may not achieve. However, CAR‑T is resource‑intensive, requiring specialized manufacturing, inpatient monitoring, and expertise to manage immune‑mediated toxicities. Access remains uneven geographically and economically, which affects who can receive these therapies.
From a systems perspective, expanding CAR‑T indications and manufacturing capacity will affect oncology practice patterns and healthcare spending. Payers and providers face decisions about which patients are best served by CAR‑T versus other approaches, and long‑term outcome data will shape value assessments. Ongoing trials investigating CAR‑T for autoimmune diseases or solid tumors could broaden the technology’s footprint but also raise new safety and cost questions.
Comparison & Data
| Item | Detail |
|---|---|
| Annual U.S. DLBCL cases | ~25,000 |
| Symptom onset | January 2024 |
| Initial diagnosis | March 2024 |
| CAR‑T infusion | January 2025 |
| Typical infusion time | 20–30 minutes |
| Post‑infusion observation | 1–2 weeks (common) |
The table summarizes case‑specific dates and typical procedural benchmarks for CAR‑T therapy. While Weiss’s infusion required only the short procedure time typical of CAR‑T, the broader care pathway includes lymphocyte collection, genetic modification, cell expansion and inpatient monitoring, extending the total treatment timeline to several weeks. Comparative outcomes across centers vary; remission durability depends on disease biology, prior therapies and patient factors. Longitudinal registries and clinical trials continue to refine expected success rates and complication profiles.
Reactions & Quotes
“It was a bit of a shock — it was very much an out‑of‑body experience.”
Debi Weiss
Weiss used the phrase to describe the emotional upheaval of an unexpected cancer diagnosis and the disorienting transition from healthy activity to intensive oncology care. That sense of disbelief is a common patient response and highlights the psychological as well as physical burden of a fast‑moving malignancy.
“When cancer recurs shortly after chemotherapy, giving more poisons isn’t usually the answer.”
Dr. Charles Farber, Hematologist‑Oncologist, Atlantic Health Morristown Medical Center
Dr. Farber framed the clinical rationale for considering CAR‑T: repeat cytotoxic regimens may offer limited benefit after early relapse, whereas targeted cellular therapies can harness the immune system to seek residual disease. He emphasized multidisciplinary evaluation before initiating complex therapies.
“The potential applications are endless.”
Dr. Mohamad Cherry, Medical Director of Hematology, Atlantic Health
Dr. Cherry’s comment reflects enthusiasm for expanding CAR‑T research but should be read in context: ongoing studies are required to establish safety, efficacy and cost‑effectiveness across new indications. Clinicians caution that translation from hematologic malignancies to other diseases is not guaranteed.
Unconfirmed
- Claims that CAR‑T will be a safe, routinely available cure for all relapsed DLBCL patients are not established and depend on individual disease and center factors.
- Early reports of CAR‑T applications in autoimmune diseases are experimental; broader clinical benefit and safety remain under investigation.
Bottom Line
Weiss’s experience highlights both the promise and complexity of modern cancer care: rapid progression of diffuse large B‑cell lymphoma can disguise itself as a common illness, but advanced immunotherapies such as CAR‑T can deliver durable remissions for select patients. Her favorable outcome—no evidence of disease as of March 2026—reflects timely diagnosis, access to specialized care and careful post‑treatment monitoring.
For clinicians and health systems, cases like this reinforce the need for early diagnostic evaluation of persistent systemic symptoms and equitable access to specialized therapies. For patients, Weiss’s story underscores the value of shared decision‑making with a multidisciplinary team and the importance of ongoing surveillance after remission.